English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17939/22958 (78%)
Visitors : 7384094      Online Users : 95
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24857


    Title: Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis
    Authors: Yen, FS;Lai, JN;Wei, JCC;Chiu, LT;Hwu, CM;Hou, MC;Hsu, CC
    Date: 2020
    Issue Date: 2022-08-09T08:09:07Z (UTC)
    Publisher: PUBLIC LIBRARY SCIENCE
    ISSN: 1932-6203
    Abstract: This study aimed to investigate the long-term outcomes of sulfonylurea (SU) use in patients with T2DM and compensated liver cirrhosis. From January 1, 2000, to December 31, 2012, we selected the data of 3781 propensity-score-matched SU users and nonusers from Taiwan's National Health Insurance Research Database. The mean follow-up time for this study was 5.74 years. Cox proportional hazards models with robust sandwich standard error estimates were used to compare the risks of main outcomes between SU users and nonusers. The incidence of mortality during follow-up was 3.24 and 4.09 per 100 person-years for SU users and nonusers, respectively. The adjusted hazard ratios and 95% confidence intervals for all-cause mortality, major cardiovascular events, and decompensated cirrhosis in SU users relative to SU nonusers were 0.79 (0.71-0.88), 0.69 (0.61-0.80), and 0.82 (0.66-1.03), respectively. The SU-associated lower risks of death and cardiovascular events seemed to have a dose-response trend. This population-based cohort study demonstrated that SU use was associated with lower risks of death and major cardiovascular events compared with SU non-use in patients with T2DM and compensated liver cirrhosis. SUs may be useful for glycemic management for patients with liver cirrhosis.
    URI: http://dx.doi.org/10.1371/journal.pone.0243783
    https://www.webofscience.com/wos/woscc/full-record/WOS:000600186100008
    https://ir.csmu.edu.tw:8080/handle/310902500/24857
    Relation: PLOS ONE ,2020 ,v15 ,issue 12
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML203View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback